BTC $79,623.75 -1.51%
ETH $2,457.67 -2.31%
BNB $747.62 +4.34%
XRP $1.40 -2.83%
SOL $102.41 -1.28%
TRX $0.3323 +1.37%
DOGE $0.0859 -1.65%
ADA $0.2132 -2.82%
BCH $251.76 -2.46%
LINK $11.78 -1.52%
HYPE $84.74 -2.14%
AAVE $130.24 -2.21%
SUI $0.7846 +1.60%
XLM $0.1831 -0.87%
ZEC $1,008.66 +1.59%
BTC $79,623.75 -1.51%
ETH $2,457.67 -2.31%
BNB $747.62 +4.34%
XRP $1.40 -2.83%
SOL $102.41 -1.28%
TRX $0.3323 +1.37%
DOGE $0.0859 -1.65%
ADA $0.2132 -2.82%
BCH $251.76 -2.46%
LINK $11.78 -1.52%
HYPE $84.74 -2.14%
AAVE $130.24 -2.21%
SUI $0.7846 +1.60%
XLM $0.1831 -0.87%
ZEC $1,008.66 +1.59%

Sonnet Biotherapeutics has received shareholder approval to merge with Hyperliquid Strategies Inc

2025-12-02 22:26:45

According to market news, Nasdaq-listed biotech company Sonnet Biotherapeutics has received shareholder approval to merge with Hyperliquid Strategies Inc.

Previously, it was reported that Hyperliquid Strategies submitted an S-1 filing to raise up to $1 billion, which may be used to purchase HYPE tokens.

app_icon
ChainCatcher Building the Web3 world with innovations.